Cancer screening test developer Grail has been spun out of biotech company Illumina with a $100m series A round co-led by Illumina and Arch Venture Partners.
US-based cancer screening technology startup Grail raised more than $100m in a series A round on Sunday co-led by biotechnology company Illumina and venture capital firm Arch Venture Partners. (Editor: subsequently increased to $125m.)
The round also featured Bezos Expeditions, the investment vehicle of e-commerce company Amazon’s chief executive Jeff Bezos, as well as VC firm Sutter Hill Ventures and Microsoft founder Bill Gates.
Illumina has retained a majority stake in Grail, which is developing cancer screening technology that will…
